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1. Introduction 
Anti–glomerular basement membrane (anti-GBM) disease is a rare autoimmune disorder 
characterized by rapidly progressive glomerulonephritis (RPGN) with diffuse crescentic 
formation on renal biopsy, and it is a well-characterized cause of glomerulonephritis.  
In 1919, an autopsy of an 18-year-old male patient, who had developed hemoptysis and 
acute renal failure after experiencing flu-like symptoms, revealed massive alveolar 
hemorrhage, glomerulonephritis with fibrinous exudates in Bowman’s capsule and 
necrotizing vasculitis in the spleen and gut (Goodpasture, 1919). Stanton and Tange 
reported 9 cases with alveolar hemorrhage and RPGN as Goodpasture’s syndrome (Stanton 
& Tange, 1958). Anti-GBM disease was defined as the presence of serum autoantibodies to 
the noncollagenous domain of the alpha 3 chain of type IV collagen or a linear binding of 
IgG to glomerular capillary walls as detected by direct immunofluorescence in patients with 
RPGN. Anti-GBM disease was divided into two types: anti-GBM disease without alveolar 
hemorrhage was regarded as renal-limited anti-GBM disease, and that with alveolar 
hemorrhage was defined as Goodpasture’s syndrome.  
This review focuses on anti-GBM disease by comparing international differences in 
prevalence, clinical features, treatments and outcomes in order to improve the prognosis of 
anti-GBM disease.  
2. Prevalence 
Anti-GBM disease is relatively rare, with an estimated annual incidence of about  
0.5-1.0/million population (Table 1). It has been estimated to cause 0.2-2.4% of biopsy-
proven glomerulonephritis cases in Europe, but less than 0.2% in Asia. It causes about 10% 
of RPGN (or necrotizing and/or crescentic glomerulonephritis) in Europe, more than 10% of 
RPGN in the United States, and less than 10% in Asia. In Japan, to improve the prognosis of 
patients with RPGN, a nation-wide survey of patients with RPGN in 365 hospitals between 
1989 and 2000 was conducted, and clinical characteristics including initial symptoms, 
laboratory findings and histological findings were investigated along with treatment 
methods and outcomes (Hirayama et al., 2008). Among patients with RPGN, 6.6% had anti-
GBM disease. In comparison with foreign countries, this Japanese rate of anti-GBM disease 
in RPGN was lower.  
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Authors Year Nation 
Incidence 
(/million/yr) 
Frequency (%) 
GN 2nd GN RPGN 
Rychlík et al. 2004 Czech 0.17 0.31 * 1.2 *  
Heaf et al. 1999 Denmark 0.6   12.8 + 
Andrassy et al. 1991 Germany 0.55   7.9 
Daly et al. 1996 Ireland  2.4 *   
Schena et al. 1997 Italy 0.1 0.20 * 1.5 *  
Grcevska et al. 1995 Macedonia    3.6 + 
Naumovic et al. 2009 Serbia 0.02 0.18 * 0.74 *  
Rivera et al. 2002 Spain    14.6 + 
Saxena et al. 1991 Sweden    13.4 + 
Williams et al. 1988 United Kingdom 1.12(0.2 – 4.0)    
Angangco et al. 1994 United Kingdom  0.81 *  11.2 + 
Parfrey et al. 1985 Canada    11.5 + 
Wilson and Dixon 1973 United States  7.0 *   
Jennette 1993 United States    14.6 + 
Briganti et al. 2001 Australia 0.99 0.8 *   
NZGS 1989 New Zealand  5.9 *   
Date et al. 1987 India  0.04 *   
Sumethkul et al. 1999 Thai  0.10 *  3.3 + 
Tang et al. 2003 China  0.15 *  8.7 + 
Li, FK. et al. 2004 China(HongKong) 0.6    
Li, LS. et al. 2004 China  0.21 * 0.86 *  
Hirayama et al. 2008 Japan    6.6 
The incidence of patients with anti-GBM disease is expressed as the number per 1 million population per year. 
The frequencies of patients with anti–GBM disease in glomerulonephritis, secondary glomerulonephritis or 
rapidly progressive glomerulonephritis are expressed as percentages. *Biopsy-proven glomerulonephritis. 
Blanks are unavailable data. Abbreviations: yr, years; GN, glomerulonephritis; 2nd GN, secondary 
glomerulonephritis; RPGN, rapidly progressive glomerulonephritis (including +necrotizing and/or crescentic 
glomerulonephritis); NZGS, The New Zealand Glomerulonephritis Study.  
Table 1. Prevalence of anti–GBM disease in various countries.  
All age groups are affected, but the peak incidence of anti-GBM disease is in the third 
decade in young men, with a second peak in the sixth and seventh decades affecting men 
and women equally (Figure 1). Alveolar hemorrhage is more common in younger men, 
while isolated renal disease is more frequent in the elderly, with a near-equal gender 
distribution. In that survey (Hirayama et al., 2008), the mean age at onset of renal-limited 
anti-GBM disease was 52.6±17.0 years. There was only one peak incidence of anti-GBM 
disease, and this peak occurred in the fifth and sixth decades. The gender distribution was 
nearly equal in renal-limited anti-GBM disease (male: female = 1: 0.94).  
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Fig. 1. Investigations of age distribution in anti-GBM disease (upper) and Goodpasture’s 
syndrome (lower). 
The histograms show the number of patients with anti-GBM disease classified by patient 
age at the onset of the disease. Abbreviations: GN, glomerulonephritis; Biopsy, biopsy-
proven glomerulonephritis; RPGN, rapidly progressive glomerulonephritis; NZGS, The 
New Zealand Glomerulonephritis Study; N.A., not available. 
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Alveolar hemorrhage is observed in 35-62% of patients with anti-GBM disease in Europe, 
the United States, and China, and it is more common in younger patients and in men, 
whereas renal-limited anti-GBM disease is more common in older patients and in women. In 
Japan, alveolar hemorrhage of patients with anti-GBM disease was less frequent (23.4%) and 
the age at onset of Goodpasture’s syndrome was lower (49.4±14.4 years), but it was more 
common in females (male: female = 1: 1.75).  
This disease appears to be more common in Caucasians and very rare in those of African 
origin (Pusey, 2003; Ooi et al., 2008). There is apparently a higher incidence of onset of 
Goodpasture’s disease in the spring and summer, as well as localized clustering of the 
disease, perhaps suggesting an infectious relationship (Pusey, 2003). Anecdotal associations 
with urinary tract infections and lithotripsy, which may subclinically affect the glomerular 
basement membrane, have also been reported (Pusey, 2003; Ooi et al., 2008).  
3. Pathogenesis 
In 1934, Masugi reported nephrotoxic glomerulonephritis induced by anti-kidney serum in 
an experimental model (Masugi, 1934), after which a linear binding of IgG to glomerular 
capillary walls was detected by direct immunofluorescence (Ortega & Mellors, 1956). In 
1964, a linear immunostaining of IgG was observed in 2 patients with Goodpasture’s 
syndrome (Scheer & Grossman, 1964), and in another study the kidney serum of patients 
with Goodpasture’s syndrome and of patients with crescentic glomerulonephritis without 
alveolar hemorrhage contained antibodies that reacted with the GBM of humans and 
animals (Lerner et al., 1967). Those authors also demonstrated that those anti-GBM 
antibodies caused glomerulonephritis when injected into animals.  
3.1 Structure of GBM 
GBM, which exists between endothelial cells and podocytes, consists of type IV collagen, 
heparansulphate proteoglycan, laminine and fibronectin. Type IV collagen, which consists 
of 3 of 6 alpha-chains (α1 to α6) encoded by three pairs of genes on chromosomes 2, 13 and 
X, and its molecules were trimeric (α1α1α2, α3α4α5 and α5α5α6). This basement membrane, 
found in kidney, lung, cochlea and eye, comprises the surface on which epithelial cells rest. 
In kidneys, α3α4α5 molecules were found in the GBM, particularly the epithelial side; 
α1α1α2 molecules were in the mesangium, the endothelial side of the GBM, tubular 
basement membranes and Bowman’s capsule; and α5α5α6 molecules were in tubular 
basement membranes and Bowman’s capsule. Each alpha-chain was made by one long 
collagenous domain and two terminal noncollagenous globular domains: the C-terminal 
noncollagenous (NC1) domain and the N-terminal domain (the 7S domain). Mature GBM is 
a lattice-like structure comprised in part by heterotrimers of α3, 4 and 5 chains, which form 
a triple helix with short NC1 and 7S domains (Sado et al., 1998). The NC1 domain of the α3 
chain of a tissue-specific type IV collagen [α3(IV)NC1] monomer is structured into the 
collagen IV network through the association of α3, α4 and α5 chains to form a triple helical 
protomer and through the oligomerization of these protomers via end-to-end associations 
and intertwining of triple helixes (Hudson et al., 2003).  
3.2 Anti-GBM antibodies 
The target of the anti-GBM antibodies was identified as α3(IV)NC1 (Saus et al., 1988). The 
two conformational epitopes of anti-GBM antibodies have been defined as EA and EB 
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(Kalluri et al., 1996; Borza et al., 2000). The EA epitope is 17-31 amino acids on the  
N-terminal side, and the EB epitope is 127-141 amino acids on the C-terminal side (Netzer et 
al., 1999). Alterations of the amino acid sequence translated by the COL4A3 gene, which 
encodes α3(IV)NC1, are not major factors, because no mutation of the COL4A3 gene was 
found (Persson et al., 2004). It was suggested that EA and EB, as cryptic B-cell epitopes, were 
enclosed in the quaternary structure of the hexamers created by sulfilimine crosslinks 
between the trimers of adjacent NC1 chains (Vanacore et al., 2008, 2009). Recently, in 
patients with Goodpasture’s disease, elevated autoantibody titers to α3(IV)NC1 and 
α5(IV)NC1 monomers at diagnosis were associated with the eventual loss of renal function 
(Pedchenko et al., 2010). In that study, these anti-GBM antibodies bound to specific epitopes 
that encompassed region EA in the α5(IV)NC1 monomer and regions EA and EB in the 
α3(IV)NC1 monomer, but did not bind to the native crosslinked α345(IV)NC1 hexamer. 
Thus, it is a dissociation of the NC1 hexamers that expose the pathogenic epitopes on the α3 
and α5 chains, precipitating the production of anti-GBM antibodies (Pedchenko et al., 2010). 
It was suggested that the autoantibody itself may subsequently alter antigen conformation 
and expose further epitopes, causing an epitope-spreading phenomenon (Salant, 2010).  
3.3 Crescent formations 
The anti-GBM antibody bound to GBM ligates Fc receptors, leading to the activation of 
monocytes, neutrophils, eosinophils, basophils and macrophages. These release chemokines 
that attract a further influx of neutrophils into glomeruli, causing severe tissue injury, 
including the disruption of the GBM. Renal injury in anti-GBM disease is amplified by the 
activation of complements and protease after the binding (Sheerin et al., 1997; Baricos et al., 
1991). The release of reactive oxygen species by neutrophils is also probably an important 
pathogenic mechanism of tissue injury.  
The histogenesis and origin of cellular crescents, which are cap-like multilayered 
accumulations of proliferating cells, have remained controversial. Although early 
ultrastructural studies suggested that crescents are formed by proliferating epithelial cells 
(Morita et al., 1973; Min et al., 1974), subsequent histochemical studies with antibodies 
against leukocytes identified the presence of monocytes-macrophages in cellular crescents 
(Atkins et al., 1976; Thomson et al., 1979). It was demonstrated that epithelial cells 
predominated in crescents of patients during the early phases of disease; later phases were 
characterized by rupture of the basement membrane of Bowman’s capsule and subsequent 
infiltration of cellular crescents, predominantly by macrophages (Boucher et al., 1987). The 
composition of cellular crescents may change during the progression of disease after the 
inciting glomerular injury (Ophascharoensuk et al., 1998).  
The main stimulus to the migration of macrophages and neutrophils is probably the 
exudation of fibrin in Bowman’s space caused by the disruption of the GBM and Bowman’s 
capsule (Tipping et al., 1988). Several possible causes of acute renal injury in anti-GBM 
disease were identified, including the functional roles of a number of macrophage 
proinflammatory mediators, such as IL-1 (Lan et al., 1993), TNF-alpha (Lan et al., 1997; Le 
Hir et al., 1998) and matrix metalloproteinase (Kaneko et al., 2003). In epithelial crescent 
formation in the glomerulus, thrombin generated by coagulation (He et al., 1991) and 
growth-factor cytokines (IL-1 and IL-2) released by monocytes and platelets (Adler et al., 
1990) stimulate the migration of epithelial cells. Moreover, interleukin-12 (Kitching et al., 
1999) and interferon-γ (Timoshanko et al., 2002) are also involved.  
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3.4 Environmental and genetic factors 
Environmental factors are thought to play a role in triggering the disease. In the first case of 
Goodpasture’s syndrome, intercurrent infection amplifies the intensity of inflammatory 
responses and can aggravate disease and so make it clinically apparent. There are a number 
of case reports of clusters of patients with anti-GBM disease (Perez et al., 1974), which may 
implicate an infective agent; however, no clear viral association has been identified. Group 
A type 12 streptococcal cell membrane shares some cross-reactivity with the human 
glomerular basement membrane, generating another hypothesis: that infection may initiate 
anti-GBM antibody production (Blue & Lange, 1975).  
Goodpasture’s syndrome has been noted to occur more frequently in smokers (Salama et al., 
2001). Lazor et al. (2007) reported that 89% of their patients with Goodpasture’s syndrome 
were active smokers. In another study, alveolar hemorrhage was present in 100% of patients 
who smoked and in only 20% of nonsmokers with Goodpasture’s disease (Donaghy & Rees, 
1983). No significant difference in circulating anti-GBM antibody titers was found between 
smokers and nonsmokers, suggesting that cigarette smoking may increase the permeability 
of lung capillaries and thus expose alveolar basement membranes to circulating anti-GBM 
antibodies (Donaghy & Rees, 1983; Klasa et al., 1988). Other inhaled substances may also be 
associated with anti-GBM disease, including cocaine (García-Rostan y Pérez et al., 1997; 
Lazor et al., 2007), hard metals such as inert tungsten carbide and cobalt (Lechleitner et al., 
1993), smoke inhalation (Klasa et al., 1988) and possibly volatile hydrocarbon solvents 
(Beirne & Brennan, 1972; Bombassei & Kaplan, 1992). In particular, hydrocarbon exposure 
may influence the development of alveolar hemorrhage (Churchill et al., 1983; Bonzel et al., 
1987). Another environmental factor, alemtuzumab, which is a humanized anti-CD52 
monoclonal antibody, recently was identified as a cause of anti-GBM disease (Clatworthy et 
al., 2008).  
Genetic factors appear to play a role in susceptibility to anti-GBM disease. As a genetic 
factor of anti-GBM disease, the human leukocyte antigen (HLA) complexes are known to 
influence susceptibility to anti-GBM disease. A strong association with HLA-DR2 specificity 
has been confirmed (Rees et al., 1978). In HLA genotyping, DRB1*1501 (the serologically 
defined HLA-DR2 gene) and DRB1*1502 (HLA-DR15 gene) allele at the DRB1 locus is 
associated with anti-GBM disease in Caucasians (Fisher et al., 1997), Chinese (Yang et al., 
2009) and Japanese (Kitagawa et al., 2008). The strongest association was with HLA 
DRB1*1501 but, when the effect of this gene was excluded, subsequent analysis revealed an 
increased frequency of DRB1*04 and DRB1*03 and a decreased frequency of DRB1*07 and 
DRB1*01 (Phelps & Rees, 1999). Other genetic influences of anti-GBM disease have been 
identified, including the immunoglobulin heavy chain Gm locus that encodes the constant 
region of the IgG heavy chain (Rees et al., 1984), polymorphisms of FCGR genes that encode 
the Fc receptor for IgG (FcγR) (Zhou et al., 2010a, 2010b) and kallikrein genes (Liu et al., 
2009).  
4. Clinical symptoms 
General malaise (fatigue), weight loss, fever, arthralgia or myalgia may be the initial features 
of anti-GBM disease in a pattern similar to but much less prominent than that in systemic 
vasculitis. Symptoms relating to anemia may also occur even in the absence of significant 
hemoptysis.  
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Authors Year Nation 
symptoms
fatigue fever dys- pnea 
hemo- 
ptysis 
macro
hemat
uria 
oligo-
anuria 
Shah et al. * 2002 Various 15% 28% 26% 65% 7% 17% 
(8/54) (15/54) (14/54) (35/54) (4/54) (9/54) 
Lazor et al. 2007 
France & 
Switzerland 
64% 43% 79% 75% 36% 18% 
(18/28) (12/28) (22/28) (21/28) (10/28) (5/28) 
Merkel et al. 1994 Germany 40% 28% 14% 51% 20% N.A. 
(14/35) (10/35) (5/35) (18/35) (7/35) 
Daly et al. 1996 Ireland N.A. N.A. N.A. 25% 35% 50% 
(10/40) (14/40) (20/40) 
Williams et al. 1988 United Kingdom N.A. N.A. 
10% 10% 10% 60% 
(1/10) (1/10) (1/10) (6/10) 
Proskey et al. * 1970 United States 
51% 22% 57% 82% 12% 
N.A. 
(29/56) (12/56) (32/56) (46/56) (7/56) 
Wilson et al. 1973 United States
34% 14% 32% 46% 42% 10% 
(17/50) (7/50) (16/50) (23/50) (21/50) (5/50) 
Briggs et al. 1979 United States
22% 11% 44% 50% 56% N.A. 
(4/18) (2/18) (8/18) (9/18) (10/18) 
Walker et al. 1985 Australia N.A. N.A. N.A. 62% N.A. 62% 
(13/21) (13/21) 
Teague et al. * 1978 New Zealand
68% 26% 78% 86% 43% N.A. 
(19/28) (7/27) (21/27) (25/29) (12/28) 
Li et al. 2004 
China
(Hong 
Kong)
N.A. N.A. N.A. 
40%
N.A. 
40% 
(4/10) (4/10) 
Cui et al. 2005 China N.A. N.A. N.A. 59% 27% 52% 
(57/97) (26/97) (50/97) 
Hirayama et al. 2008 Japan 
53% 57% 6% 15% 19% 28% 
(25/47) (27/47) (3/47) (7/47) (9/47) (13/47) 
The frequencies of patients with each symptom are expressed as percentages. *All investigated patients 
had Goodpasture’s syndrome. Abbreviations: N.A., not available. 
Table 2. Investigations of clinical symptoms in anti-GBM disease at the initial presentation.  
The principal clinical features relate to the development of renal failure due to RPGN or 
alveolar hemorrhage (Table 2). Hemoptysis is the predominant symptom of alveolar 
hemorrhage. Alveolar hemorrhage may cause severe impairment of oxygenation, so 
intensive care and artificial ventilation are sometimes needed. The mild lung symptoms are 
only dry cough and shortness of breath. Although one-third to two-thirds of patients with 
anti-GBM disease demonstrate alveolar hemorrhage in general, in our survey, 23.4% (11/47) 
of patients with anti-GBM disease suffered from alveolar hemorrhage (Hirayama et al., 
2008). A minority of patients exhibited macrohematuria. Anirua or oliguria was seen in 17-
62% of patients at presentation, and these findings suggested a poorer prognosis (Levy et al., 
2001; Hudson et al., 2003).  
5. Laboratory examinations 
In general, all patients with anti-GBM disease had microscopic hematuria on urinalysis. 
Proteinuria is modest, but can be heavier when the disease has a more subacute course. In 
our survey (Hirayama et al., 2008), the mean 24-hour excretion of urinary protein in renal-
limited anti-GBM disease was 2.1±3.0 g and that of Goodpasture’s syndrome was 3.7±3.2 
g.  
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Authors Year Nation Urinary protein(g/day)
Serum creatinine 
(mg/dL)
ESRD 
(%) 
Shah et al. 2002 Various N.A. 6.62 35% 
(27/78) (N.A.)
Herody et al. 1993 France N.A. N.A. 55% 
(16/29) 
Lazor et al. 2007 
France & 
Switzerland 
1.2 1.27 41% 
(0 – 35.0) (0.61 – 21.47) (11/28) 
Andrassy et al. 1991 Germany 6.4 12.8 67% 
(0 – 15.3) (6.1 – 16.5) (2/3) 
Merkel et al. 1994 Germany N.A. 11.41 ± 5.64 71% 
(0.2 – 3.5) (0.19 – 22.96) (20/28) 
Daly et al. 1996 Ireland N.A. 5.1 ± 6.8 50% 
(N.A.) (20/40) 
Segelmark et al. 2003 Sweden N.A. 8.94 46% 
(5.44 – 12.34) (36/79) 
Savage et al. 1986 United Kingdom N.A. N.A. 64% 
(69/108) 
Williams et al. 1988 United Kingdom N.A. 11.80 ± 4.67 70% 
(1.60 – 18.37) (7/10) 
Levy et al. 2001 United Kingdom N.A. 3.59 55% 
(0.6 – 10.9) (39/71) 
Briggs et al. 1979 United States 2.6 ± 0.5 5.94 ± 7.11 33% 
(1.9 – 3.5) (0.8 – 30.0) (6/18) 
Johnson et al. 1985 United States 4.3 ± 5.2 4.87 ± 6.93 12% 
(0 – 22.0) (0.9 - 25.0) (2/17) 
Jennette  2003 United States 1.67 ± 3.35 9.7 ± 7.2 N.A. (0.20- 16.20) (0.8 - 50)
Walker et al. 1985 Australia 1.4 6.56 45% 
(0.4 – 5.4) (1.24 – 32.35) (10/22) 
Simpson et al. 1982 New Zealand N.A. 5.37 ± 5.22 10% 
(0.68 – 19.80) (2/20) 
Teague et al. 1978 New Zealand N.A. N.A. 14% (4/29) 
Li et al. 2004 China(Hong Kong) N.A. 
6.96 ± 6.41 50% 
(1.19 – 22.09) (5/10) 
Cui et al. 2005 China N.A. N.A. 71% (69/97) 
Hirayama et al 2008 Japan 2.4 ± 3.0 7.29 ± 4.19 60% 
(0.1 – 12.2) (1.00 – 16.80) (28/47) 
Amounts of urinary protein and serum creatinine levels are expressed as means ± standard deviation or 
medians with ranges. Frequency of end-stage renal failure at presentation is expressed as a percentage. 
To convert serum creatinine in mg/dL to μmol/L, multiply by 88.4. Abbreviations: ESRD, end-stage 
renal disease; N.A., not available. 
Table 3. Investigations of renal findings in anti-GBM disease at the initial presentation.  
Unfortunately, most patients with anti-GBM disease had renal failure at the time of 
diagnosis, and the number of patients needing dialysis was not a few (Table 3). In our 
survey (Hirayama et al., 2008), the mean serum creatinine (s-Cr) level in renal-limited anti-
GBM disease was 7.07±4.21 mg/dl, while that in Goodpasture’s syndrome was 7.99±4.31 
mg/dl. Hemodialysis therapy had already been initiated in 59.6% (28/47) of the anti-GBM 
disease patients before the start of immunosuppressive treatments.  
Anemia was observed in most patients with anti-GBM disease, and the mean hemoglobin 
concentration in renal-limited anti-GBM disease was 8.8±1.7 g/dl, while that in 
Goodpasture’s syndrome was 7.5±1.1 g/dl. The mean erythrocyte sedimentation rate (ESR) 
in renal-limited anti-GBM disease was 105±44 mm/h, and that in Goodpasture’s syndrome 
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was 82±45 mm/h. The mean serum C-reactive protein (CRP) level in renal-limited anti-GBM 
disease was 8.5±7.2 mg/dl, and that in Goodpasture’s syndrome was 8.2±8.1 mg/dl. In 
comparison with other forms of RPGN, such as micropolyangiitis (MPA) and Wegener’s 
granulomatosis (WG), there was no difference in inflammation markers such as leukocyte 
count, ESR and serum CRP. However, in patients with anti-GBM disease, the mean level of 
s-Cr at the time of diagnosis was higher than that in patients with MPA (4.54±3.13 mg/dl) or 
WG (3.84±3.24 mg/dl). Therefore, early diagnosis of anti-GBM disease is very important.  
Although obvert hemoptysis may not be immediately present in patients with Goodpasture’s 
syndrome and alveolar hemorrhage may not be immediately obvious in radiological 
examinations, an elevated alveolo-arterial oxygen difference (AaPO2) can be a sensitive 
indicator of alveolar hemorrhage. An elevated red blood cell count in bronchoalveolar lavages, 
as detected by bronchoscopy, is useful information for the diagnosis of alveolar hemorrhage, 
but lung biopsy does not contribute to this diagnosis (Lazor et al., 2007).  
The diagnosis of anti-GBM disease is dependent on the detection of anti-GBM antibodies in 
either the circulation or the kidney tissue. These serum antibodies are usually detected using 
an enzyme-linked immunosorbent assay or radioimmunoassay method. The antibodies 
have not been reported to occur in the absence of disease, and false negatives are rare when 
appropriate checks are performed. In our survey (Hirayama et al., 2008), 91.5% (43/47) of 
patients with anti-GBM disease were diagnosed via the detection of serum anti-GBM 
antibodies.  
In serological examinations, other autoantibodies were not usually detected. However, in 
our survey (Hirayama et al., 2008), anti-nuclear antibodies were detected in 11.8% of renal-
limited anti-GBM disease and in 27.3% of patients with Goodpasture’s syndrome. Anti-
DNA antibody was not detected in renal-limited anti-GBM disease, but it was detected in 
22.2% of patients with Goodpasture’s syndrome. Moreover, anti-neutrophil cytoplasmic 
antibodies (ANCA) were detected in 12.8% (5/39) of patients with anti-GBM disease; a 
perinuclear pattern was detected in all five anti-GBM disease patients with ANCA, and a 
cytoplasmic pattern was detected in one. Anti-GBM antibody and ANCA coexisted in 15 - 
50% of cases of anti-GBM disease described in the previous literature (Jayne et al., 1990; 
Bosch et al., 1991; Yang et al., 2005; Rutgers et al., 2005; Levy et al., 2004). Other studies 
revealed that patients with double-positive antibodies were predominantly MPO-ANCA, 
older and male (Jayne et al., 1990; Bosch et al., 1991; Yang et al., 2005; Rutgers et al., 2005). In 
our survey (Hirayama et al., 2008), the age at onset of patients with double-positive 
antibodies was higher (mean age, 52.6 years), but female-dominant (male : female = 1 : 4). 
The prognosis of patients with double-positive antibodies varied; the renal and patient 
survival rates of patients with double-positive antibodies were reported to be either better 
(Jayne et al., 1990; Bosch et al., 1991), not significantly different (Yang et al., 2005), or worse 
(Rutgers et al., 2005; Levy et al., 2004) than those of patients with anti-GBM antibody alone. 
In our survey (Hirayama et al., 2008), the prognosis of patients with double-positive 
antibodies was poor; two died and the remaining three required maintenance hemodialysis. 
Alveolar hemorrhage was observed in two of five patients with double-positive antibodies, 
and three of them had interstitial pneumonitis.  
6. Imaging examinations 
Kidneys were usually normal-sized or enlarged due to inflammation. In our survey 
(Hirayama et al., 2008), ultrasonography showed that 61.0% of patients with anti-GBM 
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disease had kidneys of normal size, while atrophic kidneys were observed in 12.2% of 
patients and enlarged kidneys were observed in 26.8%. There were no specific 
morphological abnormalities on any type of renal imaging examinations.  
In cases with Goodpasture’s syndrome, shadows usually involve the central lung fields with 
peripheral and upper-lobe sparing on chest radiography or computed tomography  
(Figure 2). Although the shadows are generally symmetrical, they can be markedly 
asymmetrical. 
 
 
Fig. 2. Chest computed tomography in a patient with Goodpasture’s syndrome. 
Symmetrical shadows involved the central lung fields with peripheral sparing. Bilateral 
pleural effusions due to hypervolemia in acute kidney injury were also observed.  
7. Pathological findings 
A renal biopsy is essential in suspected anti-GBM disease both to confirm the diagnosis and 
to assess the renal prognosis. Glomerular fibrinoid necrosis and crescent formation with 
linear staining of the glomerular capillary walls for IgG are the histological hallmarks of 
anti-GBM disease.  
7.1 Light microscopic findings 
The histological pattern of disease starts with mesangial expansion and hypercellularity. It 
progresses to focal and segmental glomerulonephritis with infiltration by inflammatory 
cells, accompanied by segmental necrosis with prominent breaks in the GBM. Later, 
glomeruli develop an extensive crescent formation composed of parietal epithelial cells and 
macrophages in association with the destruction of the GBM (Figure 3). The crescents are 
usually at the same stage of evolution.  
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Fig. 3. Periodic acid-Schiff methenamine silver (PAM)−stained glomerulus in a patient with 
anti-GBM disease. 
The disruption of the capillary walls, segmental necrosis and cellular crescent formation are 
observed. Rupture of the basement membrane of Bowman’s capsule and periglomerular 
infiltration of inflammatory cells are also observed. Interstitial edema with infiltration of 
inflammatory cells is revealed.  
Various degrees of crescent formation are observed in more than 90% of patients with anti-
GBM disease. In Europe, the United States and Asian-Pacific, including Japan, the mean 
percentage of glomeruli showing crescent formation ranged from 40% to 100%, and about 
70% to 100% of patients with anti-GBM disease had more than 50% crescentic glomeruli 
(Figure 4). Anti-GBM disease is pathologically the most severe form of glomerulonephritis 
(Holdsworth et al., 1985; Jennette, 2003, Hirayama et al., 2008).  
Although tubules are usually normal, epithelial flattening is revealed in the severe acute 
phase. In the chronic phase, tubules in the area of severe injury undergo atrophy and some 
disappear. Acute tubulitis sometimes occurs if there is a linear staining of tubular basement 
membranes for IgG. Interstitial edema with infiltration of inflammatory cells is predominant 
in the acute phase, whereas interstitial fibrosis is revealed in the chronic phase. Interstitial 
infiltrates are composed of neutrophils, eosinophils, lymphocytes, monocytes and 
macrophages. If Bowman’s capsules are disrupted, inflammatory cells infiltrate around 
glomeruli and have a granulomatous appearance. Acute inflammation of renal vessels, 
www.intechopen.com
 
An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
262 
except for glomerular capillaries, is not typical for anti-GBM disease, unless the case has 
concurrent ANCA (Bosch et al., 1991).  
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Fig. 4. Previous investigations of crescent formation in anti-GBM disease and ANCA-
associated vasculitis. 
Each bar shows the frequency of patients with 50% or more crescents in anti-GBM disease 
(purple) and ANCA-associated vasculitis (blue). The numbers show the mean percentage of 
glomeruli showing crescent formation in anti-GBM disease. Abbreviations: UK, United 
Kingdom; USA, United States; NZ, New Zealand. 
7.2 Immunofluorescence findings 
The immunohistologic feature of anti-GBM disease is linear staining of the glomerular 
capillary walls for IgG (Figure 5). IgG1 is the predominant IgG subclass in staining of the 
glomerular capillary walls (Bowman et al., 1987; Segelmark et al., 1990). Linear staining for 
IgM and IgA is less common, but rare cases with anti-GBM disease have linear staining only 
for IgA and circulating IgA-class anti-GBM antibodies in the absence of IgG-class anti-GBM 
antibodies in the serum or staining in glomeruli (Border et al., 1979; Gris et al., 1991; Borza et 
al., 2005). Granular or discontinuous linear staining for C3 is observed in most cases with 
anti-GBM disease, but glomerular staining for C3 is negative for some cases (Wilson and 
Dixon, 1973). Irregular staining for fibrin is observed in portions of glomerular necrosis and 
cellular crescents.  
Linear staining of tubular basement membranes for IgG sometimes occurs (Lehman et al., 
1975; Andres et al., 1978).  
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Fig. 5. Direct immunofluorescence for IgG in a patient with anti-GBM disease. 
Linear staining for IgG along glomerular capillary walls is observed, but staining for IgG at 
the part of the cellular crescent is not.  
7.3 Electroscopic findings 
The rupture of GBM with variable degrees of endothelial swelling and lucent expansion of 
the subendothelial zone is common urtrasturactural findings in the acute phase of anti-GBM 
disease. Rupture of Bowman’s capsule, focal effacement of epithelial foot processes and 
accumulation of epithelial cells and macrophages in Bowman’s spaces are also observed. 
Occasionally, neutrophils are identified in capillaries, especially at sites where GBM is 
disrupted. Those findings are also observed in pauci-immune crescentic glomerulonephritis, 
but electron-dense deposits are absent, unlike the case with immune complex-type 
crescentic glomerulonephritis.  
8. Treatments 
As the pathogenesis of anti-GBM disease became clear, treatment regimens were designed 
to remove the circulating pathogenic anti-GBM antibodies by therapeutic plasma exchange, 
attenuate the pathogenic antibody-mediated glomerular inflammatory responses by 
administration of corticosteroids and suppress further production of these pathogenic 
antibodies by the use of immunosuppressive agents.  
8.1 Therapeutic plasmapheresis 
To remove the circulating pathogenic anti-GBM antibodies, therapeutic plasma exchange is 
recommended as the initial treatment. The effectiveness of therapeutic plasmapheresis for 
improving renal function has been reported. In the most commonly used regimens, plasma 
exchange of 4 L of plasma for 5% human albumin was performed daily for 14 days or until 
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the circulating anti-GBM antibodies were no longer detected (Lockwood et al., 1976). In the 
presence of alveolar hemorrhage, 300-400 ml of fresh-frozen plasma was given at the end of 
each treatment.  
To reduce the replacement of plasma,  anti-GBM antibody removal has been modified. 
Immunoadsorption to remove circulating IgG immunoglobulins without the need for 
protein substitution during daily treatments may also be beneficial in Goodpasture’s 
disease. Anecdotal case reports suggest that it may be an alternative to plasmapheresis in 
patients with severe renal failure (Laczika et al., 2000). There was a case report of 
Goodpasture’s syndrome that we treated with double filtration plasmapheresis combined 
with immunosuppression therapy (Nagasu et al., 2009). In that therapy, the removal 
efficiency for the anti-GBM antibody was 24 to 60% for each procedure.  
8.2 Corticosteroids 
To attenuate the pathogenic antibody-mediated glomerular inflammatory responses, 
corticosteroid is also a key element of this treatment. According to the most commonly used 
regimens, oral dosing of prednisolone at 1 mg/kg/day ideal body weight (maximum 80 mg 
daily) continues for at least 2 weeks, after which the dose is reduced every second week to 
30 mg by 8 weeks. After that, the dosages of prednisolone are tapered to 2.5-5.0 mg/week 
and maintained at 7.5-10 mg/kg/day. Oral corticosteroids have generally been continued 
for at least 6 months. Intravenous administration of methylprednisolone 10 mg/kg (500-
1000 mg) once daily for 1-3 days has been advocated for patients with severe alveolar 
hemorrhage or very rapid deterioration of renal function (Johnson et al., 1985).  
8.3 Immunosuppressive agents 
To further suppress the production of pathogenic anti-GBM antibodies, a combination of 
immunosuppressive agents is usually given. Among these immunosuppressive agents, 
cyclophosphamide is usually administered. According to the most commonly used 
regimens, the oral dose is 2-3 mg/kg/day (this is rounded down to the nearest 50 mg; 
reduced to 2 mg/kg/day in patients over 55 years) for 3 months. This administration is 
stopped if white blood cell counts fall below 4,000/μL. In such cases the agent is restarted at 
a lower dose once the white blood cell counts return above 4,000/μL. Intravenous 
cyclophosphamide (IVCY) is not usually administered, but it may be useful for a refractory 
case of the standard therapy (Baumgartner et al., 1995).  
Although azathioprine is sometimes used as maintenance therapy, it alone does not provide 
adequate immunosuppression to modify the disease.  
8.4 Therapeutic options for refractory diseases 
There is very little study on the treatment of refractory anti-GBM disease. Cyclosporine is 
controversial; at 6 mg/kg/day it was effective for an anti-GBM disease patient treated with 
corticosteroid, cyclophosphamide and plasma exchange (Querin et al., 1992), whereas it was 
not useful (Pepys et al., 1982). Small numbers of case reports of successful outcomes with 
mycophenolic acid or mycophenolate mofetil in patients unresponsive to or intolerant of 
standard therapy have been published (Garcia-Canton et al., 2000; Kiykim et al., 2010; Malho 
et al., 2010). Rituximab, a chimeric monoclonal anti-CD20 antibody, was effective for a case of 
relapsed anti-GBM disease that was resistant to standard treatment (Arzoo et al., 2002). In that 
case, rituximab (375 mg/m2) was administered once a week for 6 consecutive weeks; the 
symptoms completely resolved and anti-GBM antibody titers were decreased from 51 U/mL 
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to the undetectable range. However, these treatments cannot yet be recommended as a first-
line therapy because no randomized controlled trials have been carried out.  
9. Prognosis 
Most patients without treatment died shortly after diagnosis of anti-GBM disease; the 
survival rate at 12 months was 4%, and the renal survival rate was 2% (Benoit et al., 1963). 
Although mortality has improved by the introduction of intense immunosuppression, renal 
survival remains very poor because of the delayed diagnosis of anti-GBM disease or delayed 
initiation of induction therapies.  
9.1 Outcomes 
The prognosis for patients with anti-GBM disease is poor; the survival rate at 6-12 months 
was 67-94%, but the renal survival rate was 15-58% in Europe, the United States, China and 
Japan (Table 4).  
 
Authors Year Nation Treatment N 
AH 
(%) 
1-year survival 
(%) 
Patient  Renal  
Herody et al. 1993 France OCS+CYC+AZA 29 50 93 41 
Lazor et al. 2007 
France & 
Switzerland 
OCS+CYC+PE 24 100 100 58 
Merkel et al. 1994 Germany OCS+CYC+PE 35 57 89 29 
Daly et al. 1996 Ireland IS+PE 40 67 98 20 
Segelmark et al. 2003 Sweden OCS+CYC+PE 79 24 66 25 
Peters et al. 1982 United Kingdom IS+PE 41 56 76 39 
Savage et al. 1986 United Kingdom IS+PE 108 52 78 20 
Levy et al. 2001 United Kingdom OCS+CYC+PE 71 62 77 53 
Proskey et al. 1970 United States IS 56 100 77 23 
Wilson et al. 1973 United States IS 53 60 53 13 
Beirne et al. 1977 United States IS 29 54 42 17 
Briggs et al. 1979 United States IS(+PE) 18 61 84 22 
Johnson et al 1985 United States 
OCS+CYC 9 78 89 22 
OCS+CYC+PE 8 100 100 75 
Walker et al. 1985 Australia IS+PE 22 62 59 45 
Teague et al. 1978 New Zealand IS+PE 29 100 64 31 
Simpson et al. 1982 New Zealand 
no treatment 8 100 63 25 
OCS+AZA 4 100 100 50 
OCS+CYC+PE 8 100 100 63 
Li et al. 2004 
China 
(Hong Kong) 
IS+PE 10 40 70 15 
Cui et al. 2005 China IS+PE 97 58 92 22 
Hirayama et al 2008 Japan 
OCS+CYC 21 14 86 24 
OCS+CYC+PE 22 36 68 14 
Abbreviations: N, number of patients; AH, alveolar hemorrhage; IS, immunosuppressants (including 
methylprednisolone pulse therapy, oral corticosteroids, cyclophosphamide or azathioprine);  
PE, plasma exchange; OCS, oral corticosteroids; CYC, cyclophosphamide; AZA, azathioprine. 
Table 4. Investigations of treatments for anti–GBM antibody disease. 
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Renal function improves in 15-75% of patients with anti-GBM disease through the 
combination of plasma exchange with corticosteroids and immunosuppressive agents, 
whereas the renal survival rates of anti-GBM disease patients treated with 
immunosuppressive agents alone ranged from 2-22%. Improvement of renal function is 
usually evident within days of the start of plasma exchange. However, it should be 
emphasized that this regimen has never been properly assessed by a prospective 
randomized controlled trial because of the rarity and acuteness of the condition. The only 
reported randomized controlled trial was very small and used lower doses of both plasma 
exchange and cyclophosphamide than those that are generally used in practice.  
Although the effectiveness of treatment using therapeutic plasma exchange combined with 
immunosuppressive agents to improve renal function has been reported, only half of 
patients with anti-GBM disease had been treated with plasma exchange in our survey 
(Hirayama et al., 2008). Therefore, there was no significant difference in the renal survival 
rates between anti-GBM antibody disease patients treated with and without plasma 
exchange (P = 0.683 by the Log-rank Mantel-Cox test). Moreover, there was no significant 
difference in mortality between anti-GBM antibody disease patients treated with and 
without plasma exchange (P = 0.109).  
9.2 Predictors of survival 
The best predictors of renal survival are s-Cr at the initiation of treatment and the mean 
percentage of crescent formations. Renal function improves coincidentally with the 
introduction of plasma exchange in about 80-95% of patients with s-Cr levels less than or 
equal to 5.7-6.8 mg/dL (500-600 μmol/L), but in far fewer of those with higher s-Cr levels or 
those who require dialysis. Unfortunately, most patients with anti-GBM disease had renal 
failure at the time of diagnosis, and the mean percentage of crescent formation was high in 
anti-GBM disease patients. Therefore, in most patients with anti-GBM disease, the diagnosis 
may have been made too late to improve renal function by combination therapy.  
9.3 Relapse/recurrence 
Relapses of anti-GBM disease are rarely observed, in contrast to most other autoimmune 
kidney diseases. The anti-GBM antibodies seem to disappear spontaneously after 12-18 
months (Levy et al., 1996). However, several reports demonstrated recurring cases with anti-
GBM disease (Adler et al., 1981; Hind et al., 1984; Klasa et al., 1988; Levy et al., 1996). In our 
survey (Hirayama et al., 2008), relapse or recurrence was also rare in patients with anti-GBM 
disease (13.9%) in comparison with patients with ANCA-associated vasculitis, such as WG 
(29.4%) and MPA (29.3%). Therefore, remission induction therapy is more important in anti-
GBM disease. The mean time to recurrence is estimated to be 4.3 years (range, 1-10 years), 
and that late recurrence may occur with a frequency of 2-14%. During relapses, circulating 
anti-GBM antibodies often reappear. The combination of plasmapheresis and 
immunosuppressive agents as re-remission induction therapy is also successful in relapsing 
cases (Levy et al., 1996).  
10. Conclusion 
Anti-GBM disease is a rare but well-characterized glomerulonephritis. It occurs across all 
racial groups but is most common in Caucasians. Although the effectiveness of treatment 
using therapeutic plasma exchange combined with immunosuppressive agents to improve 
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renal function has been reported, the prognosis for patients with this disease is poor. To 
improve the prognosis, it may be necessary to detect this disease in earlier stages and to 
treat it without delay.  
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